Gene · 4921
NIH grants1,545
NIH grants whose papers are about the gene, through NIH's grant-paper links.
141 to 160 of 1,545
Download this page as JSON| Grant | Title | DDR2 papers | Newest fiscal year |
|---|---|---|---|
| R01AI164424 | Nonreceptor tyrosine kinases in Systemic Lupus Erythematosus | 1 | 2025 |
| R01AT011463 | Drug-gene-nutraceutical interactions of cannabidiol | 1 | 2025 |
| R01CA120813 | Modulation of Microglia and T Cell Interactions in Malignant Glioma | 1 | 2025 |
| R01CA160069 | Hepatic Stellate Cell Regulation of Metastatic Growth in the Liver | 1 | 2025 |
| R01CA175397 | Distinct Tumor and Metastatic Collagen Microenvironments: Divergent Targeting Approaches | 1 | 2025 |
| R01CA178393 | Genomic Architecture of LGL Leukemia | 1 | 2025 |
| R01CA198887 | MULTIPLEXED PROTEIN BIOMARKER-BASED ASSAY FOR THE DETECTION OF BLADDER CANCER | 1 | 2025 |
| R01CA200653 | Interaction between the Epitranscriptome and Metabolism in L-2HG Driven Kidney Cancer | 1 | 2025 |
| R01CA216101 | Mitochondrial Regulation of Antitumor Immunity | 1 | 2025 |
| R01CA235575 | Clinical translation of a NexGen platform for quantifying protein networks in human biospecimens | 1 | 2025 |
| R01CA246133 | Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasis | 1 | 2025 |
| R01CA247992 | Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translation | 1 | 2025 |
| R01CA249992 | Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC) | 1 | 2025 |
| R01CA251067 | Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2 | 1 | 2025 |
| R01CA253450 | P53, DNA Repair Imbalance, and Immune Response in Breast Cancer Mortality Disparities | 1 | 2025 |
| R01CA257153 | Mapping the regulatory landscape of RNA binding proteins and their causal roles in tumorigenesis and patient survival | 1 | 2025 |
| R01CA257612 | Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer | 1 | 2025 |
| R01CA260132 | Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem | 1 | 2025 |
| R01CA262758 | Mechanisms of venetoclax combination activity in acute myeloid leukemia | 1 | 2025 |
| R01CA262794 | EPHA2 Receptor Signaling in Breast Cancer Mechanotransduction | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4921/grants?page=8